46 results about "Drug study" patented technology

A system for predicting and summarizing medical events from electronic health records includes a computer memory storing aggregated electronic health records from a multitude of patients of diverse age, health conditions, and demographics including medications, laboratory values, diagnoses, vital signs, and medical notes. The aggregated electronic health records are converted into a single standardized data structure format and ordered arrangement per patient, e.g., into a chronological order. A computer (or computer system) executes one or more deep learning models trained on the aggregated health records to predict one or more future clinical events and summarize pertinent past medical events related to the predicted events on an input electronic health record of a patient having the standardized data structure format and ordered into a chronological order. An electronic device configured with a healthcare provider-facing interface displays the predicted one or more future clinical events and the pertinent past medical events of the patient.

A process and laser system for in vitro and in vivo pain research, pain clinical testing and pain management. In preferred embodiments of the present invention a diode laser operating at a 980 nm wavelength is used to produce warmth, tickling, itching, touch, burning, hot pain or pin-prick pain. The device and methods can be used for stimulation of a single nerve fiber, groups of nerve fibers, nerve fibers of single type only as well as more the one type of nerve fibers simultaneously. The present invention is especially useful for research of human/animal sensitivity, pain management, drug investigation and testing, and psychophysiology/electrophysiology studies. The device and methods permit non-contact, reproducible and controlled tests that avoid risk of skin damage. Applicant an his fellow workers have shown that tests with human subjects with the process and laser of the present invention correlate perfectly with laboratory tests with nerve fibers of rats. The device and the methods can be applied in a wide variety of situations involving the study and treatment of pain. Preferred embodiments of the present invention provide laser systems and techniques that permit mapping and single mode activation of C fibers and A-delta fibers.

A system for automated management of a clinical trial for pharmaceutical, biomedical, and medical device development that facilitates pharmaceutical research and reporting, including at least one site server 222, at least one computing device 218 configured to collect primary clinical trial data, and an authorized user accessible computing device 234. The central server 232 is configured to receive the primary clinical trial data from each site server 222, to store the primary clinical trial data, to create secondary clinical trial data based on the primary clinical trial data, and to transmit the primary and secondary clinical trial data to the authorized user accessible computing device 234. Also provided is a method for automatically managing a clinical trial for pharmaceutical, biomedical, and medical device development in order to facilitate pharmaceutical research and reporting, which further includes a computer readable signal containing a set of instructions to perform a corresponding method.

An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device. The method includes perfusing the organ at hypothermic and/or normothermic temperatures, preferably after hypothermic organ flushing for organ transport and/or storage. The method can be practiced with prior or subsequent static or perfusion hypothermic exposure of the organ. Organ viability is restored by restoring high energy nucleotide (e.g., ATP) levels by perfusing the organ with a medical fluid, such as an oxygenated cross-linked hemoglobin-based bicarbonate medical fluid, at normothermic temperatures. During the period in which the organ is preserved and/or maintained, various drug research and development may be performed on and/or with the organ. The organ may be perfused with a fluid containing a substance such as a test substance to obtain data regarding the organ, the substance and an interaction of the substance and the organ. The data may then be used to ultimately provide information regarding the drugs efficacy in support of regulatory filings for new drugs.

The invention discloses a medicine experiment filtering device capable of preventing medicine adhesion. The device comprises a filter box, a support plate and a base, wherein a coarse filter screen and a fine filter screen are fixed in the filter box in a horizontal state, cleaning push plates are arranged on the coarse filter screen and the fine filter screen, the cleaning push plates are connected with driving air cylinders installed on the outer wall of the filter box through piston rods, slag discharging openings are formed in the side walls of the ends, close to the coarse filter screen and the fine filter screen, of the filter box, a flushing pipe is hung on the top wall of the inner cavity of the filter box, and flushing spray heads distributed at equal intervals are arranged at thebottom of the flushing pipe. According to the invention, all the structures are matched with each other, so that medicine residues filtered out from the filter screen can be cleaned away in time, thesituation that the medicine residues are stuck to the filter screen due to long-term retention is avoided, the filter screen does not need to be removed from the filter box and then cleaned, the cleaning difficulty of the filter screen is lowered, and the filtering effect of the filter screen is guaranteed.

The present invention relates to the identification a molecular signature for PTEN tumor suppressor. The molecular signature comprising a gene or genes that are of use for diagnosis, prognosis, drug research and development and therapeutics. Specifically, the present invention relates to identification of IGFBP2 gene, its mRNA and/or protein products that closely associate with PTEN mutations. The present invention further demonstrates that IGFBP2 expression is negatively regulated by PTEN, positively regulated by PI3K and Akt activation, that IGFBP2 plays a functional role in the PTEN signaling and is required for Akt transformation. The use of IGFBP2 gene, its gene product such as its RNA transcript, protein and molecular probes in diagnosis, prognosis, drug discovery and validation and therapeutic target and therapeutics is also contemplated.

A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis. The present invention has applications in developing cost effective, controlled drug delivery vehicles from renewable resources, with a potential impact on pharmaceutical research and molecular design and delivery strategies.

The invention discloses a grinding device for medicine experiment and capable of putting medicines conveniently. The grinding device includes a base and a grinding box, hydraulic cylinders are installed on the two sides of the top of the base, and the telescopic ends of the hydraulic cylinders are connected to the grinding box through hydraulic rods; feeding hoppers are arranged at the top of thegrinding box, and a first pulverizing roller and a second pulverizing roller are arranged on the upper part of the inner cavity of the grinding box in a horizontal state; a first grinding zone and a second grinding zone are arranged on the lower part of the inner cavity of the grinding box, and grinding notches matched with grinding blocks are formed in the center positions of the first grinding zone and the second grinding zone; and a discharge port is formed in the bottom of the grinding box, and a discharge pipe is detachably installed in the discharge port. The grinding device can be usedfor putting medicines conveniently and quickly, large pieces of medicines can be pulverized into granules before the medicines are ground, and meanwhile, the pulverized medicine particles can be ground twice, so that the grinding effect of the medicines is greatly improved.

A method for evaluating drug study information to determine suitability of the drug study information for acceptance by a regulatory authority. The method includes receiving a drug study identification and study type, indicating whether the drug study is either (i) a nonclinical study that is intended to be a Good Laboratory Practice study, or (ii) a clinical study that is intended to support the efficacy indication of a drug that is the subject of the drug study information, and associating one or more checklists with the drug study. Each checklist has elements identifying one or more features to be identified in the drug study information, and a query to select a deficiency type from a predetermined list of deficiency types. The method receives the deficiency types and automatically assigns a criticality value to each based on the nature of the type of drug study.

The invention relates to a complex of a bifunctional connecting agent realizing core coordination with carbonyl metal and a preparation method thereof, and belongs to the technical field of radiopharmaceutical chemistry. The bifunctional connecting agent is N,N'-bi[2-hydroxyl-5-( propyloic) benzyl] ethylenediamine-N,N'-oxalic acid, and has a structure shown in the description, wherein at least onein R1 and R2 is a targeted small molecule or polypeptide or protein big molecule; the metal is Tc or Re. The carbonyl Tc/Re core marked HBED-CC complex is successfully obtained for the first time, different nuclide (68Ga, 99mTc/Re) marks of the same marking precursors can be realized; by aiming at the mutual supplementation of two development modes (PET/SPECT) in the same target point, the 188/186Re complex can be used for radioactive therapy medicine study. A novel idea is provided for the development of a Tc-99m single photon radioactive tracer agents and Re-188/186 radioactive treatment medicine; meanwhile, the application range of the HBED-CC derivatives as radiopharmaceutical marker precursors is also expanded.

The invention relates to a study method using capillary electrophoresis and UPLC-MS (ultra performance liquid chromatography - mass spectrometry) to analyze a regulating function of PQQ (pyrroloquinoline quinone) on catecholamine neurotransmitter, and belongs to the technical field of biological analysis. The method comprises the following steps of extracting brain tissues by anion solid-phase extraction, measuring the change of content of catecholamine in a mouse brain of a chronic stress induced depression model and the change of a reaction product of catecholamine, well separating PQQ, NE (noradrenaline), E (epinephrine) and products, and using UPLC-MS to identify the PQQ and the catecholamine reaction product. After proofing by results, the PQQ reacts with NE to generate the PQQNE, but does not react with E. The method has the advantages that the contents of NE in frontal lobe and hippocampus of the chronic stress induced depression model are obviously increased; by applying a certain amount of PQQ group, the content of NE is obviously decreased, and the contents of E in different groups are not obviously different; the PQQ is mainly used for regulating the catecholamine neurotransmitter through regulating the NE, but has no regulating function on E; the guidance meaning on the study of the depression disease mechanism and depression targeted medicine is realized.

The invention discloses a Penyanxiao enema and a preparation method thereof. The Penyanxiao enema is prepared from the following raw materials in parts by weight: 200-230 parts of giant knotweed, 100-120 parts of sargentgloryvine stem, 135-155 parts of red sage root, 60-80 parts of semen coicis, 60-80 parts of phellodendron bark, 60-80 parts of corydalis tuber, 60-80 parts of nutgrass galingale rhizome, 60-80 parts of chuanxiong rhizome, 65-85 parts of herba patriniae and 65-85 parts of dandelion. The liquid preparation disclosed by the invention is directly applied by an enema method, the drug is directly absorbed per mucous membrane of rectum, and the liquid preparation has a short distance to reach a diseased region, high local drug concentration, big contact area, short course of treatment and good curative effect. Shown by drug study and clinical research, the pharmaceutical preparation disclosed by the invention has better effects on diminishing inflammation, alleviating pain, relieving heat, detoxicating, promoting blood circulation and removing blood stasis, and has stable characters and exact curative effects.

The invention relates to an application of cephalosporin antibiotics as anticancer medicines and the anticancer medicines, and belongs to the technical field of medicine research. The cephalosporin antibiotics have a high specific anticancer effect on nasopharyngeal carcinoma, also have obvious anticancer effects on other various cancers, and have no toxicity to normal cells or have toxicity, farlower than toxicity to cancer cells, to normal cells. The cephalosporin antibiotics remarkably inhibit growth of nasopharyngeal carcinoma in vivo, and do not influence body weight development of animals. The combined effects of the cephalosporin antibiotics with clinical anticancer medicines on different cancers are different. The cephalosporin antibiotics have great differences in anticancer activity, and ceftriaxone does not have anticancer activity. The anti-cancer activity and selectivity of the cephalosporin antibiotics are determined by side chains of chemical structures of the cephalosporin antibiotics, and external structure modification of mother nuclei is a way for finding and synthesizing novel anticancer substances. The result shows that the cephalosporin antibiotics except ceftriaxone are specific anticancer medicines for nasopharyngeal carcinoma, can also be used as therapeutic medicines for other cancers, can be used as a combined anticancer medicine, or can be used as health-care products for adjuvant therapy of cancers.

The invention relates to Salmonella typhimurium X3337/pRST98lux and its application in living imaging. The above strain is preserved in China General Microbiological Culture Collection Center assigned by State Intellectual Property Office on Feb., 5, 2013, and has a preservation number of CGMCC No.7252. Lux operons compose a sexual expression luciferase and a substrate, so the bacterial luminescence can be maintained without applying a screened pressure or substrate; and the above joint mutant strain provides conveniences for constructing a cell model and an animal model, and deeply researching the pathogenic mechanisms of Salmonella typhi virulent plasmids, related medicine research and screening, the infectious disease control and the like.

A method for generating a user interface for analyzing a patient-specific electronic medical or health record that includes a problem list includes the steps of grouping related potential problems into problem list categories, grouping a subset of the problems into clusters within the categories, mapping, using a computer, entries in the problem list with a respective description in an interface terminology, associating one or more of other medical data, e.g., medication, lab results, procedures, imaging results, past medical history or surgeries, notes, vital signs, or allergy data in the record with at least one problem, receiving a request corresponding to a problem or problem list category or to other medical data, identifying non-problem data in the record grouped in a cluster with the requested data, and modifying a user interface to display the identified data separate from other similar medical data included in the electronic medical or health record.

The DNA chip with opposite method to express analyze the action mechanism of anti-tumor Chinese traditional medicine overcomes the shortcoming that it can not analyze a mass of gene expression variety. Wherein, the chip relates to apoptosis, periodic control, and drug transformation metabolism. The analysis method comprises: with objective drug as tool drug and tumor cell strain as cell model, using said Chinese drug to act on the model; screening the sensitive cell line opposite to tool drug; detecting drug-acted gene with gene expression spectrum chip; stating and classifying gene with bioinformation science; according to drug label gene and change low of special tumor gene, validating the mechanism on molecular cell level.

Compounds, compositions, methods, and uses are described herein for the treatment of respiratory diseases, including cystic fibrosis. Inhalation formulations of macrolide antibiotics are also described herein. The treatment of bacterial infections continues to be an important endeavor of pharmaceutical research and development. The specter of bacterial resistance to currently available antibiotics is ever-present, and accordingly, new and improved compounds, pharmaceuticals formulations, treatment methods, and treatment protocols are needed.

The invention discloses applications of an umbilical cord blood mesenchymal stem cell medicine in promoting the regeneration of the knee joint cartilage. The umbilical cord blood mesenchymal stem cellmedicine comprises the following ingredients: 7-9 % of umbilical cord blood mesenchymal stem cells, 1-3 % of cartilage cells, 14-17 % of hyaluronic acid gel, 3-4 % of composite nanocellulose, 15-20 %of substrate liquid, 9-11 % of traditional Chinese medicine extract sustained release microspheres, the balance of micro vacuole lubricating liquid. A preparation method of the umbilical cord blood mesenchymal stem cell medicine comprises the following steps: (1) activating the composite nanocellulose by adopting heparin; (2) preparing the cell matrix; (3) preparing the traditional Chinese medicine extract sustained release microspheres; (4) preparing the micro vacuole lubricating liquid; and (5) preparing the reagent. In short, the technical scheme has the advantages that the ratio is reasonable, the injured cartilage tissue can be effectively repaired, the cure rate is high, and the pain feeling of patients is small. The technical scheme has positive significance in drug research and clinical treatment, and has good social and economic benefits.

The invention discloses application of selenium enriched yeast in control of Alzheimer disease (AD) and an experiment of the selenium enriched yeast in treatment of three genetically modified AD mice, the experiment method of the selenium enriched yeast is as follows: every gram of mouse feed is added with 4-6 grams of selenium enriched yeast, each mouse is fed with 4 grams of the se-enriched yeast-containing feed per day, multiaspect and multichannel intensive study on the effect of the selenium enriched yeast on treatment of the three genetically modified AD mice can be performed so as to provide effective data for AD treatment drug study; the selenium enriched yeast shows excellent properties of reduction of excessive tau protein phosphorylation, significant reduction of insoluble tau protein, improvement of neuronal synaptophysin and PSD95 protein level and recovery of neuronal synapse, and selenium in the selenium enriched yeast has high absorption rate, strong biological activity, less environmental pollution and the like, and is very safe, so that the selenium enriched yeas can be used for treatment of Alzheimer disease.

The invention relates to the technical field of crymodynia tests and discloses a method and special device for measuring crymodynia behavior differences of different mice. The special device comprisesa water tank; the water tank is internally provided with a fixed plate and a thermometer; the fixed plate is provided with an electronic stopwatch and a moving assembly; and two sides of the fixed plate are provided with a first container and a second container. The two sides of the fixed plate are provided with the first container and the second container, so that a cold plate test and a fishtailing test can be simultaneously carried out; a moving block, a screw rod and other structures are arranged, so that the first container and the second container are convenient to move, and a glass plate and the tail parts of the mice are immersed in ice water for a crymodynia test; a control group I and a control group II are arranged for normal-temperature non-nerve-ligation treatment control andcold sense non-nerve-ligation control, so that the types of the control groups are added and the test precision is improved; and multiple test groups injected with different concentrations of analgesic drugs are arranged for testing the analgesic effects of the different concentrations of drugs.

The invention discloses a method for constructing a mouse model for drug research, which is particularly applied to construction of a mouse model for researching drug with a radioactive label. The constructing method disclosed by the invention is characterized in that: an inferior vena cava of a mouse is adopted as a drug administration part when the mouse is in narcosis. The method disclosed by the invention has the advantages that the operation is simple, convenient and easy, the drug absorption is fast, the drug can be effectively prevented from exposing, and the like, and the drug can be dispersed to the whole body of the mouse or target points to be inspected after the drug administration is carried out for 30min-60min.